Related Experiment Videos
[Immune replacement therapy in RS infection]
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
|January 1, 1995
Summary
New therapies targeting respiratory syncytial (RS) virus infections in infants show promise. Clinical trials of immunoglobulin and Chigain preparations demonstrated positive effects on disease symptoms and immune markers in children.
Area of Science:
- Pediatrics
- Virology
- Immunology
Background:
- Respiratory syncytial (RS) virus is a primary cause of severe respiratory infections in infants.
- Effective etiotropic therapies for RS virus infection are actively being researched.
Purpose of the Study:
- To evaluate the efficacy of novel chemo- and immune replacement therapies for RS virus infections.
- To assess the clinical and immunological impact of developed preparations in affected children.
Main Methods:
- Development and preparation of targeted immunoglobulins and Chigain.
- Clinical testing of these novel therapeutic preparations in pediatric patients.
Main Results:
- Positive clinical dynamics observed in disease manifestations.
- Favorable influence on immunological parameters in children treated with the preparations.
Conclusions:
- Developed immunoglobulin and Chigain preparations show therapeutic potential for RS virus infections.
- These targeted therapies positively impact clinical outcomes and immune status in infants and newborns.